Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel Free LSTA Stock Alerts

Lisata Therapeutics (LSTA) Financials

Lisata Therapeutics logo
$1.64 +0.07 (+4.46%)
As of 09/3/2026 04:00 PM Eastern
Compare
Annual Income Statements for Lisata Therapeutics

Annual Income Statements for Lisata Therapeutics

This table shows Lisata Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Costs & Expenses		 - - - - - - - - - 23 18
Net Income / (Loss) Attributable to Common Shareholders		 -81 -33 23 -16 -19 -8.15 -27 -54 -21 -20 -17
Consolidated Net Income / (Loss)		 -81 -33 22 -16 -19 -8.14 -27 -54 -21 -20 -17
Net Income / (Loss) Continuing Operations		 -81 -31 -16 -16 -19 -8.14 -27 -54 -21 -20 -17
Total Pre-Tax Income 		-98 -31 -28 -16 -19 -19 -29 -57 -23 -21 -18
Total Operating Income		 -114 -30 -28 -17 -20 -19 -29 -58 -26 -22 -18
Total Gross Profit		 2.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.17
Total Revenue		 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.17
Operating Revenue		 22 - - - - - - - 0.00 1.00 0.17
Total Cost of Revenue		 20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 116 30 28 17 20 19 29 58 26 23 18
Selling, General & Admin Expense		 30 13 12 9.39 9.30 9.89 11 14 13 12 10
Research & Development Expense		 24 17 16 7.59 11 9.25 18 43 13 11 7.95
Total Other Income / (Expense), net		 16 -1.76 -0.11 0.82 0.74 0.13 0.08 0.90 2.54 1.63 0.66
Interest & Investment Income		 - - - - - 0.13 0.15 1.05 2.72 1.88 0.81
Other Income / (Expense), net		 18 0.02 0.27 0.82 0.74 0.00 -0.08 -0.16 -0.19 -0.26 -0.15
Income Tax Expense		 -17 0.00 -12 - 0.00 -11 -1.51 -2.48 -2.33 -0.80 -0.96
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.12 -0.65 -0.75 -0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($16.67) ($4.99) $2.56 ($1.67) ($1.88) ($0.53) ($7.45) ($10.47) ($2.58) ($2.40) ($1.91)
Weighted Average Basic Shares Outstanding		 4.85M 6.55M 8.97M 9.69M 10.33M 15.44M 3.69M 5.18M 8.07M 8.33M 8.69M
Diluted Earnings per Share		 ($16.67) ($4.99) - ($1.67) ($1.88) ($0.53) ($7.45) ($10.47) ($2.58) ($2.40) ($1.91)
Weighted Average Diluted Shares Outstanding		 4.85M 6.55M 8.97M 9.69M 10.33M 15.44M 3.69M 5.18M 8.07M 8.33M 8.69M
Weighted Average Basic & Diluted Shares Outstanding		 4.85M 6.55M 9.55M 9.69M 10.33M 15.44M 60.53M 8.00M 8.31M 8.62M 9.03M

Quarterly Income Statements for Lisata Therapeutics

This table shows Lisata Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -2.95 -4.49 -2.93
Consolidated Net Income / (Loss)		 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -2.95 -4.49 -2.93
Net Income / (Loss) Continuing Operations		 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -2.95 -4.49 -2.93
Total Pre-Tax Income 		-5.37 -6.20 -5.04 -4.93 -1.38 -5.69 -4.66 -4.25 -2.95 -4.88 -2.93
Total Operating Income		 -6.03 -6.60 -5.52 -5.34 -0.75 -5.85 -4.87 -4.41 -3.08 -4.94 -3.99
Total Gross Profit		 - 0.00 0.00 0.00 0.17 0.00 0.07 0.00 0.10 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 0.17 0.00 0.07 0.00 0.10 0.00 0.00
Operating Revenue		 - - 0.00 0.00 - - 0.07 0.00 - - 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 6.03 6.60 5.52 5.34 0.92 5.85 4.94 4.41 3.18 4.94 3.99
Selling, General & Admin Expense		 3.01 3.36 2.92 2.79 1.35 3.25 2.69 2.46 2.05 3.74 3.41
Research & Development Expense		 3.01 3.24 2.60 2.54 -0.44 2.60 2.25 1.96 1.14 1.20 0.58
Total Other Income / (Expense), net		 0.66 0.40 0.48 0.41 -0.63 0.16 0.21 0.17 0.13 0.07 1.06
Interest & Investment Income		 0.67 0.59 0.49 0.45 -0.73 0.27 0.22 0.18 0.14 0.12 0.08
Other Income / (Expense), net		 -0.01 -0.19 -0.01 -0.05 0.10 -0.11 -0.01 -0.02 -0.02 -0.05 0.98
Income Tax Expense		 - -0.80 0.00 0.00 -0.16 -0.96 0.00 0.00 - -0.39 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 ($0.66) ($0.65) ($0.61) ($0.59) ($0.06) ($0.55) ($0.54) ($0.49) ($0.33) ($0.50) ($0.32)
Weighted Average Basic Shares Outstanding		 8.07M 8.29M 8.31M 8.32M 8.69M 8.60M 8.61M 8.74M 8.69M 9.01M 9.11M
Diluted Earnings per Share		 ($0.66) ($0.65) ($0.61) ($0.59) ($0.06) ($0.55) ($0.54) ($0.49) ($0.33) ($0.50) ($0.32)
Weighted Average Diluted Shares Outstanding		 8.07M 8.29M 8.31M 8.32M 8.69M 8.60M 8.61M 8.74M 8.69M 9.01M 9.11M
Weighted Average Basic & Diluted Shares Outstanding		 8.31M 8.31M 8.32M 8.39M 9.03M 8.60M 8.76M 8.82M 9.03M 9.11M 9.01M

Annual Cash Flow Statements for Lisata Therapeutics

This table details how cash moves in and out of Lisata Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.14 -5.61 19 -24 3.73 2.48 8.14 7.51 -9.56 -6.38 -0.25
Net Cash From Operating Activities		 -39 -24 -21 -20 -19 -8.82 -22 -21 -20 -19 -16
Net Cash From Continuing Operating Activities		 -39 -28 -20 -20 -19 -8.82 -22 -21 -20 -19 -16
Net Income / (Loss) Continuing Operations		 -81 -31 -16 -16 -19 -8.14 -27 -54 -21 -20 -17
Consolidated Net Income / (Loss)		 -81 -33 22 -16 -19 -8.14 -27 -54 -21 -20 -17
Depreciation Expense		 2.69 0.45 0.37 0.23 0.07 0.06 0.06 0.07 0.19 0.17 0.15
Amortization Expense		 - - - - 0.23 0.31 2.51 0.79 -0.96 -0.46 -0.08
Non-Cash Adjustments To Reconcile Net Income		 54 2.36 2.52 1.31 1.30 1.27 2.01 33 2.04 1.78 1.85
Changes in Operating Assets and Liabilities, net		 -15 0.22 -6.95 -5.35 -1.12 -2.32 0.65 -0.83 -0.46 -0.87 -1.29
Net Cash From Investing Activities		 3.80 -2.85 41 -4.71 21 -7.28 -55 29 10 13 15
Net Cash From Continuing Investing Activities		 3.80 -1.10 41 -4.71 21 -7.28 -55 29 10 13 15
Purchase of Property, Plant & Equipment		 -3.19 -1.10 -0.14 -0.13 0.00 -0.02 -0.06 -0.29 - 0.00 -0.03
Purchase of Investments		 -6.08 0.00 -60 -70 -33 -35 -180 -90 -98 -56 -9.18
Sale and/or Maturity of Investments		 13 0.00 34 63 54 28 125 122 109 69 24
Net Cash From Financing Activities		 37 21 -0.93 0.82 1.18 19 85 -0.22 0.39 -0.21 0.60
Net Cash From Continuing Financing Activities		 37 17 -0.86 0.82 1.18 19 85 -0.22 0.39 -0.21 0.60
Issuance of Common Equity		 36 12 5.70 1.03 1.31 19 86 0.04 0.32 0.07 0.84
Other Financing Activities, net		 0.00 -0.07 -0.35 -0.05 -0.13 -0.15 -0.22 -0.27 0.06 -0.27 -0.25
Effect of Exchange Rate Changes		 - - - - - - 0.00 -0.01 -0.02 -0.06 0.01

Quarterly Cash Flow Statements for Lisata Therapeutics

This table details how cash moves in and out of Lisata Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -9.84 -0.79 6.49 -8.78 2.83 4.01 -3.38 2.16 -3.04 -2.90 -2.62
Net Cash From Operating Activities		 -4.07 -7.03 -5.28 -2.52 -1.12 -5.40 -3.96 -3.34 -3.25 -3.08 -2.65
Net Cash From Continuing Operating Activities		 -4.07 -7.03 -5.28 -2.52 -1.12 -5.40 -3.96 -3.34 -3.25 -3.08 -2.65
Net Income / (Loss) Continuing Operations		 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -2.95 -4.49 -2.93
Consolidated Net Income / (Loss)		 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -2.95 -4.49 -2.93
Depreciation Expense		 0.05 0.05 0.05 0.04 0.01 0.04 0.04 0.04 0.02 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.47 0.55 0.24 0.36 0.71 0.53 0.24 0.23 0.85 0.36 0.21
Changes in Operating Assets and Liabilities, net		 1.03 -2.07 -0.39 2.10 -0.93 -1.21 0.44 0.65 -1.16 1.04 0.06
Net Cash From Financing Activities		 0.02 -0.14 0.03 - 0.71 -0.02 0.06 0.35 0.21 0.18 0.03
Net Cash From Continuing Financing Activities		 0.02 -0.14 0.03 - 0.71 -0.02 0.06 0.35 0.21 0.18 0.03
Issuance of Common Equity		 0.02 0.00 0.03 - 0.81 0.21 0.07 0.35 0.21 0.00 0.03
Effect of Exchange Rate Changes		 -0.08 -0.06 0.03 0.04 0.00 0.00 0.01 0.00 0.00 0.01 0.00

Annual Balance Sheets for Lisata Therapeutics

This table presents Lisata Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 57 54 63 45 27 36 97 73 55 35 18
Total Current Assets		 29 25 61 44 26 35 96 72 54 35 18
Cash & Equivalents		 20 7.08 29 10 14 17 25 32 23 16 16
Prepaid Expenses		 3.48 1.90 1.31 1.05 0.82 0.76 1.21 2.65 3.39 2.43 1.75
Plant, Property, & Equipment, net		 17 0.71 0.26 0.17 0.10 0.06 0.06 0.30 0.18 0.07 0.02
Total Noncurrent Assets		 11 28 1.72 0.31 1.08 0.61 0.76 0.86 0.60 0.35 0.02
Other Noncurrent Operating Assets		 0.98 1.58 1.72 0.31 1.08 0.61 0.76 0.53 0.33 0.16 0.02
Total Liabilities & Shareholders' Equity		 57 54 63 45 27 36 97 73 55 35 18
Total Liabilities		 34 30 13 7.13 6.60 3.76 5.01 6.71 6.80 5.69 3.14
Total Current Liabilities		 21 21 9.31 5.62 5.98 3.51 4.52 6.38 6.59 5.61 3.07
Accounts Payable		 4.11 3.91 1.34 0.76 1.49 1.02 1.93 2.66 2.42 1.28 1.02
Accrued Expenses		 6.20 2.66 7.81 4.86 4.49 2.49 2.59 3.73 4.17 4.33 2.05
Total Noncurrent Liabilities		 13 8.87 3.87 1.51 0.62 0.25 0.49 0.33 0.21 0.07 0.07
Other Noncurrent Operating Liabilities		 0.56 0.39 3.87 1.51 0.62 0.25 0.49 0.33 0.21 0.07 0.07
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 23 4.07 50 37 21 32 92 66 48 29 15
Total Preferred & Common Equity		 24 4.88 51 38 21 32 92 67 48 30 15
Total Common Equity		 24 4.88 51 38 21 32 92 67 48 30 15
Common Stock		 397 410 433 436 439 459 546 575 577 578 580
Retained Earnings		 -372 -405 -382 -398 -417 -426 -453 -507 -528 -548 -565
Treasury Stock		 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 -0.03 -0.03 0.00 -0.01 -0.07 -0.03 -0.04 -0.08 -0.04
Noncontrolling Interest		 -0.43 -0.82 -0.32 -0.27 -0.26 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25

Quarterly Balance Sheets for Lisata Therapeutics

This table presents Lisata Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 58 48 43 38 29 25 22 14 11
Total Current Assets		 57 48 42 38 29 25 22 14 11
Cash & Equivalents		 32 22 28 20 20 17 19 13 10
Prepaid Expenses		 2.84 4.21 3.72 1.84 2.03 2.41 2.08 0.96 0.57
Plant, Property, & Equipment, net		 0.20 0.15 0.12 0.10 0.07 0.05 0.02 0.02 0.01
Total Noncurrent Assets		 0.65 0.54 0.47 0.41 0.29 0.23 0.16 0.02 0.00
Other Noncurrent Operating Assets		 0.37 0.29 0.25 0.20 0.12 0.07 0.02 0.02 0.00
Total Liabilities & Shareholders' Equity		 58 48 43 38 29 25 22 14 11
Total Liabilities		 5.39 5.50 4.58 4.76 3.88 4.39 4.64 3.39 3.04
Total Current Liabilities		 5.13 5.33 4.46 4.69 3.81 4.31 4.57 3.32 2.99
Accounts Payable		 1.31 1.26 0.73 0.56 0.60 0.78 0.62 0.51 0.84
Accrued Expenses		 3.82 4.07 3.73 4.14 3.21 3.53 3.95 2.81 2.15
Total Noncurrent Liabilities		 0.25 0.16 0.12 0.07 0.07 0.07 0.07 0.07 0.05
Other Noncurrent Operating Liabilities		 0.25 0.16 0.12 0.07 0.07 0.07 0.07 0.07 0.05
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 53 43 38 33 25 21 17 11 7.99
Total Preferred & Common Equity		 53 43 38 34 25 21 17 11 8.24
Total Common Equity		 53 43 38 34 25 21 17 11 8.24
Common Stock		 576 577 578 578 579 579 580 581 581
Retained Earnings		 -523 -533 -539 -543 -553 -557 -562 -569 -572
Treasury Stock		 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71
Accumulated Other Comprehensive Income / (Loss)		 -0.10 -0.10 -0.08 -0.03 -0.08 -0.05 -0.04 -0.02 -0.02
Noncontrolling Interest		 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25

Annual Metrics And Ratios for Lisata Therapeutics

This table displays calculated financial ratios and metrics derived from Lisata Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2025
DEI Shares Outstanding		 55,373,251.00 8,169,407.00 9,470,860.00 9,841,983.00 10,399,930.00 19,395,977.00 59,779,855.00 7,859,684.00 8,139,449.00 8,820,733.00 8,820,733.00
DEI Adjusted Shares Outstanding		 5,537,325.00 8,169,407.00 9,470,860.00 9,841,983.00 10,399,930.00 19,395,977.00 59,779,855.00 7,859,684.00 8,139,449.00 8,820,733.00 8,820,733.00
DEI Earnings Per Adjusted Shares Outstanding		 -14.61 -4.00 2.43 -1.64 -1.86 -0.42 -0.46 -6.90 -2.56 -1.88 -1.88
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 25.36% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -83.00%
EBITDA Growth		 -77.55% 68.93% 7.16% 40.86% -19.56% 1.47% -41.44% -114.26% 53.14% 30.11% 20.33%
EBIT Growth		 -75.36% 69.33% 7.32% 40.84% -19.73% 1.07% -52.13% -98.30% 55.17% 29.12% 19.02%
NOPAT Growth		 -97.17% 74.09% 6.47% 38.44% -18.28% 4.71% -51.74% -98.28% 55.37% 29.17% 18.74%
Net Income Growth		 -46.05% 58.88% 166.73% -172.74% -19.69% 57.93% -237.38% -97.43% 61.57% 20.41% 17.01%
EPS Growth		 -46.05% 70.07% 0.00% 0.00% -12.57% 71.81% -1,305.66% -40.54% 75.36% 25.97% 20.42%
Operating Cash Flow Growth		 16.29% 39.71% 11.80% 4.26% 5.52% 53.27% -152.13% 4.83% 5.38% 3.37% 17.60%
Free Cash Flow Firm Growth		 25.97% 103.35% -815.21% -31.29% 6.05% -4.08% -25.66% -105.06% 54.80% 23.14% 18.78%
Invested Capital Growth		 -59.29% -113.33% -270.15% 42.50% 17.77% 49.37% -27.41% 2.29% 8.99% 48.69% 29.72%
Revenue Q/Q Growth		 11.30% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -84.11%
EBITDA Q/Q Growth		 -58.90% 58.19% -7.61% 18.24% -6.51% -2.66% -3.40% -0.65% 1.35% 22.96% 9.49%
EBIT Q/Q Growth		 -56.80% 58.23% -7.45% 18.33% -7.77% -3.04% -4.74% 0.49% 1.94% 22.70% 9.22%
NOPAT Q/Q Growth		 -63.36% 64.84% -7.92% 17.18% -6.84% -1.94% -5.07% 0.53% 1.97% 22.47% 9.31%
Net Income Q/Q Growth		 -36.22% 44.90% 16.78% -4.27% -7.77% -6.25% -5.22% 1.46% 2.91% 20.03% 9.08%
EPS Q/Q Growth		 -36.22% 47.31% 0.00% -4.38% -6.21% 18.46% -211.72% 27.59% 22.99% 23.90% 10.33%
Operating Cash Flow Q/Q Growth		 5.25% 18.44% -2.93% 4.44% -6.65% -18.02% 4.15% -9.66% 10.70% -2.43% 7.42%
Free Cash Flow Firm Q/Q Growth		 -13.22% 104.49% -181.67% 20.37% -5.12% -7.78% 3.45% -4.87% 10.62% 10.68% 8.74%
Invested Capital Q/Q Growth		 -53.51% -112.10% 12.38% -4.84% -10.17% 16.21% -71.08% 22.80% -56.27% 44.01% 27.89%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 10.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin		 -415.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,961.76% -10,754.71%
Operating Margin		 -506.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,711.18% -10,711.18%
EBIT Margin		 -427.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,796.47% -10,796.47%
Profit (Net Income) Margin		 -360.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,756.47% -9,756.47%
Tax Burden Percent		 82.45% 106.56% -80.25% 100.00% 100.00% 42.82% 94.80% 95.63% 89.94% 94.52% 94.52%
Interest Burden Percent		 102.21% 106.04% 101.38% 100.03% 100.00% 99.31% 99.48% 98.18% 89.48% 95.61% 95.61%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -233.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -213.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 34.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -199.15% -142.50% 60.36% -36.90% -66.72% -30.84% -44.21% -68.50% -36.49% -53.08% -75.53%
Cash Return on Invested Capital (CROIC)		 -149.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -104.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -50.68% -69.59%
Return on Assets (ROA)		 -88.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -45.79% -62.89%
Return on Common Equity (ROCE)		 -201.28% -87.17% 45.39% -37.14% -67.34% -31.14% -44.39% -68.72% -36.65% -53.51% -76.41%
Return on Equity Simple (ROE_SIMPLE)		 -341.62% -682.03% 44.01% -42.86% -92.97% -25.05% -29.77% -81.45% -43.28% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -80 -21 -19 -12 -14 -13 -20 -40 -18 -13 -13
NOPAT Margin		 -354.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,497.82% -7,497.82%
Net Nonoperating Expense Percent (NNEP)		 -19.99% -85.38% 96.59% -8.31% -15.50% 17.61% -11.01% -16.94% -4.75% -11.55% -16.27%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -37.57% -87.30% -87.30%
Cost of Revenue to Revenue		 89.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 133.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,135.29% 6,135.29%
R&D to Revenue		 106.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,675.88% 4,675.88%
Operating Expenses to Revenue		 516.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10,811.18% 10,811.18%
Earnings before Interest and Taxes (EBIT)		 -96 -29 -27 -16 -19 -19 -29 -58 -26 -18 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -93 -29 -27 -16 -19 -19 -27 -57 -27 -19 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.52 4.73 0.66 0.93 1.25 0.85 0.55 0.30 0.46 1.10 1.10
Price to Tangible Book Value (P/TBV)		 4.32 4.73 0.66 0.93 1.25 0.85 0.55 0.30 0.46 1.10 1.10
Price to Revenue (P/Rev)		 2.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.51 96.51
Price to Earnings (P/E)		 0.00 0.00 1.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 69.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.16 1.16
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 24.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.72 0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.49 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.16 -0.63 -1.17 -1.18 -1.18 -1.13 -1.04 -1.04 -1.05 -1.06 -1.07
Leverage Ratio		 2.26 2.37 1.59 1.23 1.24 1.20 1.07 1.07 1.12 1.16 1.20
Compound Leverage Factor		 2.31 2.51 1.61 1.23 1.24 1.19 1.07 1.05 1.00 1.11 1.15
Debt to Total Capital		 41.88% 21.36% 0.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 13.39% 12.37% 0.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 28.49% 8.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -1.07% 62.27% -0.63% -0.73% -1.28% -0.79% -0.28% -0.38% -0.53% -1.74% -1.74%
Common Equity to Total Capital		 59.20% 16.37% 100.32% 100.73% 101.28% 100.79% 100.28% 100.38% 100.53% 101.74% 101.74%
Debt to EBITDA		 -0.18 -0.22 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.04 0.02 2.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.12 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.21 -0.31 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.04 0.03 3.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.14 -0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -13.03 -11.87 -7.36 -9.71 -20.62 -12.82 -0.37 -9.48 -12.08 -43.83 -43.83
Noncontrolling Interest Sharing Ratio		 -1.07% 38.83% 24.80% -0.67% -0.92% -0.98% -0.41% -0.32% -0.44% -0.81% -1.16%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.39 1.16 6.59 7.85 4.35 10.08 21.27 11.26 8.18 5.76 5.76
Quick Ratio		 1.09 0.34 5.91 7.66 4.21 9.86 21.00 10.85 7.67 5.20 5.20
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -51 1.71 -12 -16 -15 -16 -20 -40 -18 -14 -13
Operating Cash Flow to CapEx		 -1,232.32% -2,152.66% -15,463.70% 0.00% 0.00% -44,115.00% -37,075.00% -7,428.07% 0.00% 0.00% -56,960.71%
Free Cash Flow to Firm to Interest Expense		 -23.94 0.96 -32.30 -3,205.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -18.44 -13.30 -55.23 -3,997.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -19.94 -13.92 -55.58 -3,514.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Accounts Receivable Turnover		 7.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.76 3.78
Accounts Payable Turnover		 4.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 46.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 88.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -42.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 20 -2.63 -9.74 -5.60 -4.60 -2.33 -2.97 -2.90 -2.64 -1.36 -1.36
Invested Capital Turnover		 0.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.09 -0.10
Increase / (Decrease) in Invested Capital		 -29 -22 -7.11 4.14 1.00 2.27 -0.64 0.07 0.26 1.29 0.57
Enterprise Value (EV)		 56 41 -27 -8.29 0.68 -7.09 -45 -50 -29 0.20 0.20
Market Capitalization		 60 23 33 35 26 28 50 20 22 16 16
Book Value per Share		 $0.43 $0.60 $5.33 $3.83 $2.00 $1.68 $1.54 $8.47 $5.92 $1.68 $1.68
Tangible Book Value per Share		 $0.25 $0.60 $5.33 $3.83 $2.00 $1.68 $1.54 $8.43 $5.88 $1.68 $1.68
Total Capital		 40 30 50 37 21 32 92 66 48 15 15
Total Debt		 17 6.37 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 11 2.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -3.54 -0.70 -60 -43 -25 -35 -95 -69 -51 -16 -16
Capital Expenditures (CapEx)		 3.19 1.10 0.14 -2.42 0.00 0.02 0.06 0.29 0.00 0.00 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.70 0.08 -7.84 -4.57 -5.16 -2.75 -3.31 -3.73 -3.20 -1.32 -1.32
Debt-free Net Working Capital (DFNWC)		 14 7.16 52 38 20 32 92 65 47 15 15
Net Working Capital (NWC)		 8.26 3.47 52 38 20 32 92 65 47 15 15
Net Nonoperating Expense (NNE)		 1.32 13 -42 4.28 5.29 -5.26 7.13 14 2.84 3.84 3.84
Net Nonoperating Obligations (NNO)		 -3.56 -26 -60 -43 -25 -35 -95 -69 -51 -16 -16
Total Depreciation and Amortization (D&A)		 2.69 0.45 0.37 0.23 0.30 0.37 2.57 0.86 -0.77 -0.28 0.07
Debt-free, Cash-free Net Working Capital to Revenue		 -29.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -778.82% -778.82%
Debt-free Net Working Capital to Revenue		 60.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8,607.06% 8,607.06%
Net Working Capital to Revenue		 36.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8,607.06% 8,607.06%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($16.70) ($4.99) $2.56 ($1.67) ($1.88) ($0.53) ($0.50) ($10.47) ($2.58) ($1.91) ($1.91)
Adjusted Weighted Average Basic Shares Outstanding		 5.90M 8.31M 8.97M 9.69M 10.64M 59.51M 55.31M 5.18M 8.07M 8.69M 8.69M
Adjusted Diluted Earnings per Share		 ($16.70) ($4.99) $2.56 $0.00 ($1.88) ($0.53) ($0.50) ($10.47) ($2.58) ($1.91) ($1.91)
Adjusted Weighted Average Diluted Shares Outstanding		 5.90M 8.31M 8.97M 9.69M 10.64M 59.51M 55.31M 5.18M 8.07M 8.69M 8.69M
Adjusted Basic & Diluted Earnings per Share		 ($16.70) ($4.99) $0.00 $0.00 ($1.88) ($0.53) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.85M 6.55M 9.55M 9.95M 10.33M 15.44M 60.53M 8.00M 8.31M 9.03M 9.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -36 -21 -19 -12 -14 -13 -20 -40 -18 -13 -13
Normalized NOPAT Margin		 -160.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,497.82% -7,497.82%
Pre Tax Income Margin		 -436.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,322.35% -10,322.35%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -45.16 -16.56 -72.28 -3,232.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -37.44 -11.60 -51.10 -2,378.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -46.66 -17.18 -72.63 -2,749.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -38.94 -12.22 -51.46 -1,894.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 45.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 45.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Lisata Therapeutics

This table displays calculated financial ratios and metrics derived from Lisata Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 8,139,449.00 8,307,433.00 8,307,433.00 8,319,600.00 8,820,733.00 8,620,162.00 8,598,204.00 8,755,948.00 8,820,733.00 9,032,291.00 9,106,391.00
DEI Adjusted Shares Outstanding		 8,139,449.00 8,307,433.00 8,307,433.00 8,319,600.00 8,820,733.00 8,620,162.00 8,598,204.00 8,755,948.00 8,820,733.00 9,032,291.00 9,106,391.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.66 -0.65 -0.61 -0.59 -0.14 -0.55 -0.54 -0.49 -0.33 -0.50 -0.32
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -90.00% 0.00% -100.00%
EBITDA Growth		 5.53% 1.18% 22.27% 12.57% 94.65% 13.69% 13.76% 18.93% 38.38% 16.07% 38.05%
EBIT Growth		 7.80% 1.01% 21.18% 9.94% 89.27% 12.32% 11.96% 17.64% 37.60% 16.06% 38.30%
NOPAT Growth		 7.89% 3.55% 19.67% 10.53% 87.57% 11.42% 11.86% 17.28% 37.77% 15.48% 18.00%
Net Income Growth		 10.43% 12.70% -25.25% 6.29% 77.43% 12.53% 7.63% 13.81% 35.92% 4.97% 37.13%
EPS Growth		 53.85% 15.58% -22.00% 9.23% 90.91% 15.38% 11.48% 16.95% 40.00% 9.09% 40.74%
Operating Cash Flow Growth		 37.09% 14.26% -26.27% 29.72% 72.45% 23.13% 25.12% -32.72% 28.25% 42.93% 33.04%
Free Cash Flow Firm Growth		 3.62% 5.78% 36.48% 51.87% 59.58% 9.96% 31.11% -20.82% 34.67% 54.58% 38.04%
Invested Capital Growth		 8.99% -54.59% 0.00% -43.20% 48.69% -20.63% -347.57% 22.36% 29.72% -226.68% -105.27%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.48% -10.46% 18.41% 3.47% 93.85% -1,681.44% 18.47% 9.26% 30.03% 0.00% 39.83%
EBIT Q/Q Growth		 -1.04% -12.44% 18.43% 2.82% 87.96% -818.52% 18.09% 9.09% 30.17% 0.00% 39.79%
NOPAT Q/Q Growth		 -1.02% -9.56% 16.33% 3.39% 85.96% -680.64% 16.74% 9.33% 30.22% 0.00% 19.22%
Net Income Q/Q Growth		 -1.98% -0.67% 6.61% 2.26% 75.44% -290.09% 1.38% 8.80% 30.48% 0.00% 34.75%
EPS Q/Q Growth		 -1.54% 1.52% 6.15% 3.28% 89.83% -816.67% 1.82% 9.26% 32.65% 0.00% 36.00%
Operating Cash Flow Q/Q Growth		 -13.56% -72.70% 24.82% 52.34% 55.48% -381.89% 26.77% 15.52% 2.78% 0.00% 14.08%
Free Cash Flow Firm Q/Q Growth		 28.27% 1.60% 18.33% 16.50% 39.76% -119.18% 37.51% -46.43% 24.84% 0.00% 14.76%
Invested Capital Q/Q Growth		 -56.27% 77.05% 55.94% -806.37% 44.01% 46.05% -63.47% -57.24% 27.89% 0.00% -2.72%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 100.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -196.47% 0.00% -6,930.00% 0.00% -3,080.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -440.59% 0.00% -6,954.29% 0.00% -3,080.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -381.18% 0.00% -6,964.29% 0.00% -3,095.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -712.35% 0.00% -6,655.71% 0.00% -2,954.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 87.13% 100.00% 100.00% 88.07% 83.08% 100.00% 100.00% 100.00% 92.06% 100.00%
Interest Burden Percent		 88.87% 91.32% 91.10% 91.62% 212.19% 95.53% 95.57% 95.87% 95.44% 97.60% 97.37%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -36.49% -38.77% -55.46% -48.15% -53.08% -46.90% -64.40% -72.17% -75.53% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -1.79% 0.00% -220.04% 0.00% -19.95% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -3.34% 0.00% -210.29% 0.00% -19.04% 0.00% 0.00%
Return on Common Equity (ROCE)		 -36.65% -38.96% -55.83% -48.44% -53.51% -47.25% -64.95% -72.89% -76.41% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -46.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.22 -4.62 -3.87 -3.74 -0.52 -4.09 -3.41 -3.09 -2.16 -3.46 -2.79
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -308.41% 0.00% -4,868.00% 0.00% -2,156.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.92% -1.49% -6.16% -2.65% -2.07% -1.82% -4.16% -4.23% -3.38% -5.29% -0.83%
Return On Investment Capital (ROIC_SIMPLE)		 -8.81% -10.81% -10.18% -11.17% -3.59% -16.31% -16.40% -18.05% -14.77% -32.42% -34.97%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 796.47% 0.00% 3,835.71% 0.00% 2,045.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% -255.88% 0.00% 3,218.57% 0.00% 1,135.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 540.59% 0.00% 7,054.29% 0.00% 3,180.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -6.04 -6.79 -5.54 -5.38 -0.65 -5.95 -4.88 -4.43 -3.10 -5.00 -3.01
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.24 -6.89 -5.63 -5.43 -0.33 -5.95 -4.85 -4.40 -3.08 -4.99 -3.01
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.46 0.60 0.75 0.74 1.10 0.80 1.19 1.32 1.10 4.14 3.76
Price to Tangible Book Value (P/TBV)		 0.46 0.61 0.76 0.75 1.10 0.80 1.19 1.33 1.10 4.14 3.76
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 96.51 119.16 23.30 21.44 96.51 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 1.16 0.00 2.53 3.45 1.16 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.27 16.11
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.01 -1.01 -1.05 -1.06 -1.02 -1.02 -1.09 -1.07 -1.09 -1.13
Leverage Ratio		 1.12 1.11 1.12 1.12 1.16 1.14 1.15 1.19 1.20 1.20 1.26
Compound Leverage Factor		 0.99 1.01 1.02 1.02 2.46 1.09 1.10 1.14 1.15 1.17 1.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.53% -0.59% -0.67% -0.76% -1.74% -1.01% -1.22% -1.48% -1.74% -2.38% -3.18%
Common Equity to Total Capital		 100.53% 100.59% 100.67% 100.76% 101.74% 101.01% 101.22% 101.48% 101.74% 102.38% 103.18%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -10.88 -12.07 -13.30 -16.20 -40.54 -23.22 -27.22 -32.86 -41.00 -48.92 -66.54
Noncontrolling Interest Sharing Ratio		 -0.44% -0.49% -0.67% -0.59% -0.81% -0.75% -0.86% -1.00% -1.16% -1.42% -1.77%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.18 8.92 9.42 8.04 5.76 7.52 5.77 4.72 5.76 4.23 3.69
Quick Ratio		 7.67 8.13 8.58 7.64 5.20 6.98 5.21 4.27 5.20 3.94 3.50
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.48 -4.41 -3.60 -3.01 -1.81 -3.97 -2.48 -3.63 -2.73 -1.80 -1.54
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -4,003.57% -19,292.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.04 0.01 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 1.76 1.55 12.81 18.14 3.78 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.64 -0.61 -0.27 -2.42 -1.36 -0.73 -1.20 -1.88 -1.36 -2.39 -2.45
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.09 -0.25 -1.46 -0.50 -0.10 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.26 -0.21 -0.27 -0.73 1.29 -0.13 -0.93 0.54 0.57 -1.66 -1.26
Enterprise Value (EV)		 -29 -18 -9.69 -11 0.20 -5.83 2.70 3.69 0.20 32 20
Market Capitalization		 22 26 29 25 16 20 25 23 16 45 31
Book Value per Share		 $5.92 $5.18 $4.60 $4.05 $1.68 $2.94 $2.45 $1.98 $1.68 $1.21 $0.91
Tangible Book Value per Share		 $5.88 $5.15 $4.58 $4.02 $1.68 $2.92 $2.43 $1.97 $1.68 $1.21 $0.91
Total Capital		 48 43 38 33 15 25 21 17 15 11 7.99
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -51 -43 -38 -36 -16 -26 -22 -19 -16 -13 -10
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.03 0.03 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.20 -1.12 -0.74 -2.86 -1.32 -1.02 -1.40 -1.99 -1.32 -2.36 -2.42
Debt-free Net Working Capital (DFNWC)		 47 42 38 33 15 25 21 17 15 11 8.03
Net Working Capital (NWC)		 47 42 38 33 15 25 21 17 15 11 8.03
Net Nonoperating Expense (NNE)		 1.15 0.78 1.18 1.19 0.69 0.63 1.25 1.16 0.80 1.03 0.13
Net Nonoperating Obligations (NNO)		 -51 -43 -38 -36 -16 -26 -22 -19 -16 -13 -10
Total Depreciation and Amortization (D&A)		 -0.20 -0.11 -0.09 -0.05 0.31 0.00 0.02 0.03 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -778.82% -601.76% -130.65% -186.07% -778.82% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 8,607.06% 14,594.12% 1,922.62% 1,589.44% 8,607.06% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 8,607.06% 14,594.12% 1,922.62% 1,589.44% 8,607.06% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.66) ($0.65) ($0.61) ($0.59) ($0.06) ($0.55) ($0.54) ($0.49) ($0.33) ($0.50) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 8.07M 8.29M 8.31M 8.32M 8.69M 8.60M 8.61M 8.74M 8.69M 9.01M 9.11M
Adjusted Diluted Earnings per Share		 ($0.66) ($0.65) ($0.61) ($0.59) ($0.06) ($0.55) ($0.54) ($0.49) ($0.33) ($0.50) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 8.07M 8.29M 8.31M 8.32M 8.69M 8.60M 8.61M 8.74M 8.69M 9.01M 9.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.31M 8.31M 8.32M 8.39M 9.03M 8.60M 8.76M 8.82M 9.03M 9.11M 9.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.22 -4.62 -3.87 -3.74 -0.52 -4.09 -3.41 -3.09 -2.16 -3.46 -2.79
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -308.41% 0.00% -4,868.00% 0.00% -2,156.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -808.82% 0.00% -6,655.71% 0.00% -2,954.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Lisata Therapeutics’ Q2 2026 results show improving quarterly spending and losses, but the company remains pre-revenue and continues to consume cash. Net loss narrowed to $2.9 million, or $0.32 per share, from $4.5 million, or $0.50 per share, in Q1 2026 and $4.7 million, or $0.54 per share, in Q2 2025.

Operating expenses declined to $4.0 million in Q2 from $4.9 million in both Q1 2026 and Q2 2025. Research and development spending fell to $584,000 from $1.2 million in Q1 and $2.3 million a year earlier, while selling, general and administrative costs decreased modestly to $3.4 million. This cost reduction helped operating cash flow improve to a quarterly outflow of $2.6 million, compared with $3.1 million in Q1 2026 and $4.0 million in Q2 2025.

However, Lisata reported no revenue in Q2 2026, continuing a broader pattern of limited commercial revenue. The company’s cash position has also deteriorated significantly, declining from $38.2 million of cash and short-term investments in Q3 2024 to $10.4 million of cash at the end of Q2 2026. At the latest quarterly operating burn rate, the company has approximately four quarters of cash coverage before considering future financing, capital requirements or changes in spending.

  • Quarterly losses improved: Q2 2026 net loss narrowed approximately 35% from Q1 2026 and 37% from Q2 2025.
  • Operating expenses declined: Total operating expenses fell to $4.0 million, with research and development expense down substantially from the prior-year period.
  • Cash burn moderated: Operating cash outflow improved to $2.6 million in Q2 2026 from $3.1 million in Q1 and $4.0 million in Q2 2025.
  • Balance-sheet leverage remains limited: Total liabilities were $3.0 million against $11.0 million of current assets, and the data shows only $50,000 of noncurrent liabilities.
  • Other income supported results: Interest and investment income plus other income contributed $1.1 million in Q2 2026, but these amounts can fluctuate and are not a substitute for operating revenue.
  • Financial data includes restated and calculated periods: Investors should review the company’s filings when comparing historical quarters because some supplied 2024 and 2025 figures were restated or calculated.
  • Revenue remains absent: Lisata reported zero revenue in Q2 2026 and Q1 2026, leaving the company dependent on cash reserves and financing while it develops its programs.
  • Cash reserves have fallen sharply: Cash declined from $13.1 million at the end of Q1 2026 to $10.4 million at the end of Q2, while cash and investments have dropped from more than $38 million in mid-2024.
  • Continued financing may be necessary: Lisata has generated recurring operating losses and negative operating cash flow. The $29,000 of common-equity proceeds in Q2 2026 was immaterial relative to the quarterly cash burn.
  • Shareholder dilution remains a risk: Weighted-average basic shares increased to 9.1 million in Q2 2026 from 8.6 million in Q2 2025, potentially reducing each existing shareholder’s ownership percentage if additional equity is issued.
09/04/26 12:54 AM ETAI Generated. May Contain Errors.

Lisata Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lisata Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Lisata Therapeutics' net income appears to be on a downward trend, with a most recent value of -$16.59 million in 2025, falling from -$81.01 million in 2015. The previous period was -$19.99 million in 2024. See where experts think Lisata Therapeutics is headed by visiting Lisata Therapeutics' forecast page.

Lisata Therapeutics' total operating income in 2025 was -$18.21 million, based on the following breakdown:
  • Total Gross Profit: $170 thousand
  • Total Operating Expenses: $18.38 million

Over the last 10 years, Lisata Therapeutics' total revenue changed from $22.49 million in 2015 to $170 thousand in 2025, a change of -99.2%.

Lisata Therapeutics' total liabilities were at $3.14 million at the end of 2025, a 44.7% decrease from 2024, and a 90.7% decrease since 2015.

In the past 10 years, Lisata Therapeutics' cash and equivalents has ranged from $7.08 million in 2016 to $32.15 million in 2022, and is currently $15.96 million as of their latest financial filing in 2025.

Over the last 10 years, Lisata Therapeutics' book value per share changed from 0.43 in 2015 to 1.68 in 2025, a change of 293.3%.


Related Companies

Financial statements for NASDAQ:LSTA last updated on 9/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel